AstraZeneca Makes $10 Billion Offer to Acquire Obesity Drugmaker Rhythm Pharmaceuticals
The non-binding bid values the rare obesity drugmaker at up to $134 a share.
The non-binding bid values the rare obesity drugmaker at up to $134 a share.
AstraZeneca posted solid 9M and Q3 results, beat forecasts, and launched a $1.5bn savings plan to fund its pipeline.
Amgen and AstraZeneca’s Tezspire showed high histologic remission and symptom improvement in Phase 3 EoE trial, positioning it as a potential Dupixent rival.
Summit and AstraZeneca will co-develop ivonescimab combinations, starting with GI cancers. Each company keeps rights to its own medicines.
Citi calls Olema’s drop after AstraZeneca’s SERENA-4 miss excessive, keeps Buy and $59 target, and sees $20 value from later-line use.
The Phase III SERENA-4 trial did not meet its primary PFS endpoint in untreated advanced ER-positive, HER2-negative breast cancer, despite a numerical benefit.